T0	PROCESS 0 1	primary efficacy end point
T0	PROCESS 0 1	iv ceftriaxone treatment
T0	PROCESS 0 1	physical functioning
T0	PROCESS 0 1	clinical significance
T0	PROCESS 0 1	long-term effect
T0	PROCESS 0 1	long-term benefit
T0	PROCESS 0 1	ceftriaxone group
T0	PROCESS 0 1	affected patient
T0	PROCESS 0 1	troubling aspect
T0	PROCESS 0 1	posttreatment lyme disease
T0	PROCESS 0 1	primary interest
T0	PROCESS 0 1	adverse effect
T0	PROCESS 0 1	iv ceftriaxone
T0	PROCESS 0 1	limited duration
T0	PROCESS 0 1	cognitive improvement
T0	PROCESS 0 1	effective strategy
T0	PROCESS 0 1	sustained cognitive improvement
T0	PROCESS 0 1	certain subgroup
T0	PROCESS 0 1	neurologic abnormality
T0	PROCESS 0 1	predictor analysis
T0	PROCESS 0 1	independent confirmation
T0	PROCESS 0 1	treatment strategy
